Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves Β· freshest Wall Street data, updated daily View live feed β†’
Analyst Tracker/Mark Massaro
BTIG

Mark Massaro

Wall Street Analyst
β˜…β˜…β˜…β˜…β˜…
#241
on 13Foresight Β· ranked by our own returns
63%
Success Rate
+13.9%
Average Return
47 of 75 calls profitable Β· -196.9% vs benchmark
S&P 500 (SPY)
πŸ“ˆ Across the calls we could measure, roughly 63% of Mark Massaro's ratings turned a profit when each position was held for 1 year β€” averaging +13.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

93 Buy 22 Hold 2 Sell
Mark's Stock Coverage 37 ratings Β· 2026-11-15
Company Date Position Consensus β“˜ Price Target β“˜ 1-Yr Return vs S&P 500 β“˜
CAI
Caris Life Sciences, Inc.
Oct 27, 2026 BUY Strong Buy
-9.5% avg upside
21 analysts
$38.00
10.69% Upside
-32.0% Β·
GH
Guardant Health
Oct 27, 2026 BUY Strong Buy
-3.1% avg upside
33 analysts
$210.00
17.51% Upside
-14.8% Β·
NTRA
Natera
Oct 27, 2026 BUY Strong Buy
-13.3% avg upside
28 analysts
$430.00
3.81% Upside
-22.3% Β·
CDNA
CareDx
Oct 27, 2026 BUY Strong Buy
-41.0% avg upside
18 analysts
$81.00
7.38% Downside
+10.4% Β·
IMDX
Insight Molecular Diagnostics
Oct 20, 2026 HOLD Buy
+79.9% avg upside
10 analysts
β€” -17.8% Β·
MDXH
MDxHealth
Oct 19, 2026 HOLD Buy
+3860.3% avg upside
9 analysts
β€” -33.3% Β·
PSNL
Personalis
Oct 06, 2026 HOLD Buy
-6.1% avg upside
11 analysts
β€” -2.0% Β·
NEO
NeoGenomics
Oct 06, 2026 BUY Strong Buy
+19.1% avg upside
19 analysts
$28.00
61.18% Upside
-3.0% Β·
ADPT
Adaptive Biotechnologies
Sep 22, 2026 BUY Strong Buy
+1.9% avg upside
17 analysts
$34.00
27.58% Upside
+3.5% Β·
DNA
Ginkgo Bioworks Holdings
Sep 04, 2026 SELL Strong Sell
-32.3% avg upside
6 analysts
$5.00
55.48% Downside
-47.5% Β·
MXCT
MaxCyte
Aug 24, 2026 HOLD Strong Buy
+151.6% avg upside
5 analysts
β€” -14.4% Β·
TEM
Tempus AI, Inc. Class A
Aug 20, 2026 BUY Buy
-0.3% avg upside
25 analysts
$80.00
10.80% Upside
+7.4% Β·
LUCD
Lucid Diagnostics
Aug 17, 2026 BUY Strong Buy
+1104.3% avg upside
8 analysts
$2.50
517.63% Upside
-57.4% Β·
FRNM
Freenome Inc
Aug 17, 2026 BUY Strong Buy
+44.3% avg upside
4 analysts
$17.00
36.31% Upside
-19.4% Β·
CERS
Cerus
Aug 14, 2026 BUY Strong Buy
+135.7% avg upside
10 analysts
$4.00
75.51% Upside
-34.6% Β·
TKNO
Alpha Teknova
Aug 11, 2026 BUY Strong Buy
+74.1% avg upside
8 analysts
$8.00
8.69% Upside
+24.4% Β·
BLLN
BillionToOne, Inc. Class A
Aug 06, 2026 BUY Strong Buy
+12.2% avg upside
10 analysts
$130.00
14.72% Upside
+14.7% Β·
XGN
Exagen
Aug 05, 2026 BUY Strong Buy
+50.2% avg upside
11 analysts
$9.00
4.87% Upside
-37.9% Β·
SOPH
SOPHiA GENETICS
Aug 05, 2026 BUY Strong Buy
+36.9% avg upside
8 analysts
$9.00
18.05% Upside
+30.3% Β·
WGS
GeneDx Holdings
Aug 04, 2026 BUY Strong Buy
+22.6% avg upside
10 analysts
$90.00
30.25% Upside
-26.1% Β·
CSTL
Castle Biosciences
Aug 03, 2026 BUY Strong Buy
+16.9% avg upside
10 analysts
$44.00
18.49% Upside
+11.2% Β·
ZTS
Zoetis
Feb 26, 2026 BUY Buy
+43.7% avg upside
25 analysts
$160.00
100.79% Upside
-35.4% Β·
IDXX
Idexx Laboratories
Feb 03, 2026 BUY Buy
+30.3% avg upside
19 analysts
$800.00
45.12% Upside
+9.5% Β·
BNGO
BioNano Genomics
Aug 22, 2025 HOLD Buy
+722.6% avg upside
9 analysts
β€” -70.0% Β·
RNLXY
Renalytix
May 20, 2024 BUY Strong Buy
+190.7% avg upside
5 analysts
$2.00
45.99% Downside
Β· Β·
HLTHQ
Cue Health
Mar 21, 2024 HOLD Hold
2 analysts
β€” Β· Β·
TTOO
T2 Biosystems
Sep 22, 2023 HOLD Buy
+1015078.6% avg upside
10 analysts
β€” Β· Β·
HTGMQ
HTG Molecular Diagnostics
Dec 06, 2019 HOLD Strong Buy
+733333233.4% avg upside
6 analysts
β€” Β· Β·
QDEL
QuidelOrtho
Nov 17, 2019 BUY Strong Buy
+195.9% avg upside
13 analysts
$75.00
466.09% Upside
+201.7% Β·
OSUR
Orasure Technologies
Nov 10, 2019 HOLD Buy
+111.5% avg upside
12 analysts
$8.00
103.03% Upside
+54.8% Β·
QTRX
Quanterix
Nov 06, 2019 BUY Buy
+548.5% avg upside
8 analysts
$35.00
1104.84% Upside
+157.7% Β·
LH
Labcorp Holdings
Oct 24, 2019 HOLD Strong Buy
-21.6% avg upside
38 analysts
$170.00
52.91% Downside
+26.3% Β·
ILMN
Illumina
Oct 24, 2019 HOLD Strong Buy
-10.1% avg upside
32 analysts
$310.00
31.31% Upside
+2.5% Β·
DGX
Quest Diagnostics
Oct 22, 2019 BUY Buy
-26.4% avg upside
34 analysts
$113.00
55.14% Downside
+28.2% Β·
AWHL
Aspira Women's Health
May 23, 2018 HOLD Buy
+2471.5% avg upside
6 analysts
$1.00
376.25% Upside
Β· Β·
RIOT
Riot Platforms
Feb 09, 2016 HOLD Strong Buy
+124.9% avg upside
30 analysts
$4.00
68.83% Downside
Β· Β·
BDX
Becton Dickinson
May 07, 2015 HOLD Buy
-0.4% avg upside
25 analysts
$145.00
26.78% Downside
+17.5% Β·
πŸ”’ 32 more ratings β€” with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Mark Massaro β€” Frequently Asked Questions
How accurate are Mark Massaro's stock ratings?
Based on the calls 13Foresight could measure, about 63% of Mark's ratings were profitable over a one-year hold, with an average return of +13.8% per rating, or -196.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Mark ranked on 13Foresight?
Mark Massaro is currently ranked #241 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge β€” so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Mark cover?
Mark most recently has ratings on CAI, GH, NTRA, CDNA, IMDX, MDXH, PSNL, NEO, ADPT, DNA, MXCT, TEM and 25 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.